|
2014 Conference Publication Interaction of an antitumor peptide with lipids of the cancer plasma membrane - Formation of membrane domains and influence of cholesterolRiedl, Sabrina, Rinner, Beate, Rechberger, Gerald, Schaider, Helmut, Lohner, Karl and Zweytick, Dagmar (2014). Interaction of an antitumor peptide with lipids of the cancer plasma membrane - Formation of membrane domains and influence of cholesterol. 58th Annual Meeting of the Biophysical-Society, San Francisco United States, Feb 15-19, 2014. St. Louis, United States: Cell Press. doi: 10.1016/j.bpj.2013.11.558 |
|
2014 Conference Publication Patients with aggressive B-cell lymphomas display distinct chemokine receptor profile and an association of low CCR7 expression and favorable cancer specific survivalWenzl, K., Troppan, K., Pursche, B., Schaider, H., Beham-Schmid, C., Deutsch, A. and Neumeister, P. (2014). Patients with aggressive B-cell lymphomas display distinct chemokine receptor profile and an association of low CCR7 expression and favorable cancer specific survival. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg Germany, 10-14 October 2014. Basel, Switzerland: S Karger AG. doi: 10.1159/000368945 |
|
2014 Conference Publication BRAF mutations in an involuting and non-involuting naevus upon BRAF +/- MEK treatmentMcClenahan, P., Lin, L., Tan, J. M., Smith, R. Flewell, Schaider, H., Jagirdar, K., Lambie, D., Prow, T. W., Sturm, R. A. and Soyer, H. P. (2014). BRAF mutations in an involuting and non-involuting naevus upon BRAF +/- MEK treatment. The Australasian College of Dermatologists 47th Annual Scientific Meeting, Melbourne Australia, 18–21 May 2014. Richmond Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/ajd.12174 |
|
2014 Conference Publication Antitumor peptides derived of human Lactoferricin as cancer therapy targeting the membrane lipid phosphatidylserine exposed by malignant melanoma and glioblastomaRiedl, Sabrina, Rinner, Beate, Schaider, Helmut, Asslaber, Martin, Lohner, Karl and Zweytick, Dagmar (2014). Antitumor peptides derived of human Lactoferricin as cancer therapy targeting the membrane lipid phosphatidylserine exposed by malignant melanoma and glioblastoma. 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, Athens, Greece, October 9-11, 2014. Athens, Greece: Spandidos Publications. |
|
2014 Conference Publication THz QCL self-mixing interferometry for biomedical applicationsRakić, Aleksandar, Taimre, Thomas, Bertling, Karl, Lim, Yah Leng, Wilson, Stephen J., Nikolić, Milan, Valavanis, Alexander, Indjin, Dragan, Linfield, Edmund H., Davies, A. Giles, Ferguson, Blake, Walker, Graeme, Schaider, Helmut and Soyer, H. Peter (2014). THz QCL self-mixing interferometry for biomedical applications. SPIE Optical Engineering + Applications Conference 2014, San Diego, United States, 17-21 August 2014. Bellingham, WA, United States: S P I E - International Society for Optical Engineering. doi: 10.1117/12.2061433 |
|
2014 Conference Publication Human lactoferricin derivatives as new targeted weapons in cancer therapyRiedl, Sabrina, Rinner, Beate, Schaider, Helmut, Lohner, Karl and Zweytick, Dagmar (2014). Human lactoferricin derivatives as new targeted weapons in cancer therapy. 58th Annual Meeting of the Biophysical-Society, San Francisco United States, Feb 15-19, 2014. St. Louis, United States: Cell Press. doi: 10.1016/j.bpj.2013.11.554 |
|
2014 Conference Publication Distinct chemokine receptor profiles in Richter's transformation compared to de-novo diffuse large B-cell lymphoma and germinal center B-cellsTroppan, K. T., Wenzl, K., Pursche, B., Schaider, H., Beham-Schmid, C., Deutsch, A. and Neumeister, P. (2014). Distinct chemokine receptor profiles in Richter's transformation compared to de-novo diffuse large B-cell lymphoma and germinal center B-cells. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, 10-14 October 2014. Basel, Switzerland: S. Karger AG. doi: 10.1159/000368945 |
|
2013 Conference Publication Cd271+ve drug tolerant stem like melanoma cells play a crucial role in resistance to BRAF inhibitorsMenon, D. R., Das, S., Rinner, B., Bonyadirad, E., Hoefler, G. and Schaider, H. (2013). Cd271+ve drug tolerant stem like melanoma cells play a crucial role in resistance to BRAF inhibitors. 40th Annual Meeting of the Association-of-Dermatological-Research, Dessau Germany, Mar 14-16, 2013. West Sussex United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/exd.12072 |
|
2013 Conference Publication Notch4 mediated regulation of Slug and Twist1 in melanomaBonyadirad, E., Popper, U., Wels, C., Menon, D. R. and Schaider, H. (2013). Notch4 mediated regulation of Slug and Twist1 in melanoma. 40th Annual Meeting of the Association-of-Dermatological-Research, Dessau Germany, Mar 14-16, 2013. West Sussex United Kingdom: Wiley Blackwell Publishing. doi: 10.1111/exd.12072 |
|
2013 Conference Publication High expression of CXCR4 and CXCR7 is associated with an advanced stage in aggressive lymphomaDeutsch, A., Pichler, M., Beham-Schmid, C., Schaider, H. and Neumeister, P. (2013). High expression of CXCR4 and CXCR7 is associated with an advanced stage in aggressive lymphoma. Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Oncology, Vienna, Austria, 18-22 October 2013. Basel, Switzerland: S. Karger AG. doi: 10.1159/000356365 |
|
2013 Conference Publication In vitro effects of dimethylacrylshikonin on melanoma cellsKretschmer, N., Rinner, B., Deutsch, A., Lohberger, B., Schaider, H. and Bauer, R. (2013). In vitro effects of dimethylacrylshikonin on melanoma cells. 8th World Congress of Melanoma, 9th Congress of the European Association of Dermatology (EADO), 7th Interdisciplinary Melanoma/Skin Cancer Meeting, 3rd European Post-Chicago Melanoma Meeting 2013, Hamburg, Germany, 17-20 July 2013. Berlin, Germany: Wiley-Blackwell Verlag GmbH. doi: 10.1111/ddg.12163 |
|
2012 Conference Publication Transient CD271+ve Drug Tolerant Stem Like Melanoma Cells Are Inherently Resistant Towards BRAF And MEK InhibitionMenon, D. R., Das, S., Rinner, B., Heike, K., Bonyadirad, E., Hoefler, G. and Schaider, H. (2012). Transient CD271+ve Drug Tolerant Stem Like Melanoma Cells Are Inherently Resistant Towards BRAF And MEK Inhibition. 42nd Annual Meeting of the European-Society-for-Dermatological-Research (ESDR), Venice Italy, Sep 07-10, 2012. NATURE PUBLISHING GROUP. |
|
2012 Conference Publication Confocal: laser scanning microscopy, a useful complement in the diagnosis of regressive lesions?Niederkorn, Anna, Arzberger, Edith, Wurm, Elisabeth M. T., Richtig, Erika, Fink-Puches, Regina, Schaider, Helmut, Wolf, Ingrid H. and Hofmann-Wellenhof, Rainer (2012). Confocal: laser scanning microscopy, a useful complement in the diagnosis of regressive lesions?. WILEY-BLACKWELL. doi: 10.1111/j.1610-0387.2012.08011.x |
|
2012 Conference Publication The role(s) of the junction protein ZO-1 in malignant melanomaBohner, C., Pandjaitan, M. A., Haass, N. K., Zorn-Kruppa, M., Moll, I., von den Driesch, P., Schaider, H. and Brandner, J. M. (2012). The role(s) of the junction protein ZO-1 in malignant melanoma. 39th Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Marburg Germany, Mar 01-03, 2012. WILEY-BLACKWELL. |
|
2012 Conference Publication TGF-beta1 abrogates whereas TNF-alpha enhances resistance to ERK inhibitors in BRAF mutant melanoma cells through Twist1Menon, D., Wels, C., Rinner, B., Brandner, J. M. and Schaider, H. (2012). TGF-beta1 abrogates whereas TNF-alpha enhances resistance to ERK inhibitors in BRAF mutant melanoma cells through Twist1. 39th Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Marburg Germany, Mar 01-03, 2012. WILEY-BLACKWELL. |
|
2011 Conference Publication The viral chemokine receptor US28 mediates its anti-tumorigenic effect in melanoma via GNA13Joshi, Shripad, Wels, Christian, Fukunaga-Kalabis, Mizuho, Herlyn, Meenhard and Schaider, Helmut (2011). The viral chemokine receptor US28 mediates its anti-tumorigenic effect in melanoma via GNA13. 41st Annual Meeting of the European-Society-for-Dermatological-Research, Barcelona Spain, Sep 07-10, 2011. NATURE PUBLISHING GROUP. |
|
2011 Conference Publication Targeting the cancer cell membrane specifically with human lactoferricin derivativesRiedl, S., Rinner, B., Tumer, S., Schaider, H., Lohner, K. and Zweytick, D. (2011). Targeting the cancer cell membrane specifically with human lactoferricin derivatives. 9th International Symposium on Targeted Anticancer Therapies, Paris France, Mar 07-09, 2011. OXFORD UNIV PRESS. |
|
2011 Conference Publication In search of new targets - the membrane lipid phosphatidylserine - the underestimated Achilles' Heel of cancer cellsZweytick, D., Riedl, S., Rinner, B., Asslaber, M., Schaider, H., Walzer, S., Novak, A. and Lohner, K. (2011). In search of new targets - the membrane lipid phosphatidylserine - the underestimated Achilles' Heel of cancer cells. 9th International Symposium on Targeted Anticancer Therapies, Paris France, Mar 07-09, 2011. OXFORD UNIV PRESS. |
|
2011 Conference Publication Slug augments the epithelial-mesenchymal like transition in melanoma through transcriptional activation of ZEB1Wels, C., Joshi, S. and Schaider, H. (2011). Slug augments the epithelial-mesenchymal like transition in melanoma through transcriptional activation of ZEB1. 38th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung, Tuebingen Germany, Feb 17-19, 2011. WILEY-BLACKWELL PUBLISHING, INC. |
|
2011 Conference Publication Differential expression of ZO-1 in melanoma and nevi and their tumor microenvironment - an indicator of malignancyBohner, C., Haass, N. K., Vidal-y-Sy, S., Moll, I., von den Driesch, P., Schaider, H. and Brandner, J. (2011). Differential expression of ZO-1 in melanoma and nevi and their tumor microenvironment - an indicator of malignancy. 38th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung, Tuebingen Germany, Feb 17-19, 2011. WILEY-BLACKWELL PUBLISHING, INC. |
